Πέμπτη 8 Φεβρουαρίου 2018

Talazoparib Bests Chemo for Breast Cancer [News in Brief]

Patients with advanced or metastatic HER2-negative breast cancer and germline BRCA1/2 mutations may benefit from talazoparib, according to data from a phase III trial. Compared with chemotherapy, the investigational PARP inhibitor induced some complete responses, prolonged progression-free survival, and improved patients' overall quality of life.



http://ift.tt/2nUHfjt

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου